Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies

The American Journal of Medicine
James Thrasher

Abstract

Choices for the treatment of type 2 diabetes mellitus (T2DM) have multiplied as our understanding of the underlying pathophysiologic defects has evolved. Treatment should target multiple defects in T2DM and follow a patient-centered approach that considers factors beyond glycemic control, including cardiovascular risk reduction. The American Association of Clinical Endocrinologists/American College of Endocrinology and the American Diabetes Association recommend an initial approach consisting of lifestyle changes and monotherapy, preferably with metformin. Therapy choices are guided by glycemic efficacy, safety profiles, particularly effects on weight and hypoglycemia risk, tolerability, patient comorbidities, route of administration, patient preference, and cost. Balancing management of hyperglycemia with the risk of hypoglycemia and consideration of the effects of pharmacotherapy on weight figure prominently in US-based T2DM recommendations, whereas less emphasis has been placed on the ability of specific medications to affect cardiovascular outcomes. This is likely because, until recently, specific glucose-lowering agents have not been shown to affect cardiorenal outcomes. The Empagliflozin Cardiovascular Outcome Event Trial...Continue Reading

References

Aug 5, 2000·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·M FüchtenbuschH Schatz
Sep 24, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·M PeyrotS E Skovlund
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Nov 11, 2008·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Muhammad A Abdul-Ghani, Ralph A DeFronzo
May 21, 2010·Diabetes Care·Diana SherifaliHertzel C Gerstein
Jan 26, 2012·Diabetes Care·Jennifer A HirstRichard J Stevens
May 23, 2012·Clinical Therapeutics·Vanita R ArodaByron J Hoogwerf
Jun 23, 2012·Pharmacogenetics and Genomics·Li GongTeri E Klein
Feb 19, 2013·Diabetology & Metabolic Syndrome·Lilian Beatriz Aguayo Rojas, Marilia Brito Gomes
Jun 20, 2013·Mediators of Inflammation·Francisco A MonsalveRodrigo Moore-Carrasco
Aug 2, 2013·Diabetes Care·Ralph A DeFronzoMuhammad Abdul-Ghani
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Dec 26, 2013·JAMA : the Journal of the American Medical Association·Mike Mitka
Feb 28, 2014·The New England Journal of Medicine·Amy G EganCurtis Rosebraugh
Jan 30, 2015·Expert Opinion on Drug Safety·André J Scheen
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Oct 30, 2015·Diabetes, Obesity & Metabolism·Sten Madsbad
Oct 30, 2015·Expert Opinion on Drug Safety·André J Scheen
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Dec 24, 2015·Diabetes Care·UNKNOWN American Diabetes Association
Jan 9, 2016·The Journal of Endocrinology·Hongying An, Ling He
Jan 29, 2016·European Heart Journal·David FitchettUNKNOWN EMPA-REG OUTCOME® trial investigators
Feb 18, 2016·The New England Journal of Medicine·Walter N KernanUNKNOWN IRIS Trial Investigators
Mar 18, 2016·The New England Journal of Medicine·Bernard ZinmanSilvio E Inzucchi
Apr 16, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Yehuda HandelsmanMatthew R Weir
Apr 18, 2016·Clinical Therapeutics·Sven KohlerUli C Broedl
Jun 25, 2016·Nature Reviews. Endocrinology·Abd A TahraniClifford J Bailey
Nov 1, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Joel Zonszein, Per-Henrik Groop

❮ Previous
Next ❯

Citations

May 21, 2017·The American Journal of Medicine·Leigh Perreault
May 21, 2017·The American Journal of Medicine·Christoph Wanner
Dec 21, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Marie Jazmín Sarabia-SánchezAlfredo Téllez-Valencia
Nov 18, 2017·Journal of Enzyme Inhibition and Medicinal Chemistry·Eisuke KatoJun Kawabata
Dec 23, 2017·Diabetes & Metabolism Journal·Hyun Jin KimUNKNOWN Committee of Clinical Practice Guidelines of the Korean Diabetes Association
Apr 25, 2018·Diabetes, Obesity & Metabolism·Dong-Mei LiuJian-Min Liu
May 31, 2018·American Journal of Physiology. Renal Physiology·Aurélie Edwards, Olivier Bonny
Oct 15, 2018·Journal of Cellular Physiology·Yaser KhajebishakBeitollah Alipour
Dec 7, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Irene RomeraJesús Reviriego
Feb 19, 2019·Bioscience, Biotechnology, and Biochemistry·Eisuke Kato
Apr 10, 2019·Immunological Investigations·Humera InayatAkhter Ali Baloch
Mar 29, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Nataliya TemelkovaPlamen Popivanov
Jun 14, 2019·Post Reproductive Health·John C Stevenson
Nov 30, 2018·Endocrine, Metabolic & Immune Disorders Drug Targets·Haroon KhanAtanas G Atanasov
Aug 8, 2018·Current Diabetes Reviews·Mohammad J AlkhatatbehMohammad A Y Alqudah
Apr 17, 2019·Current Hypertension Reviews·Michail NatsisVasilios Kotsis
Jun 4, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Csaba HegedűsRita Kiss
Aug 1, 2018·Expert Review of Endocrinology & Metabolism·Ashley M HigbeaJooyeon Chae
Aug 29, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Dhiren K Patel, Jodi Strong
Jul 24, 2020·Indian Journal of Endocrinology and Metabolism·Rajeev ChawlaUNKNOWN RSSDI-ESI Consensus Group
Jun 24, 2017·American Journal of Respiratory and Critical Care Medicine·Mary S M Ip, David Wong
May 22, 2021·Nature Communications·Nairie MichaelianVadim Cherezov
Oct 15, 2020·Revista da Escola de Enfermagem da U S P·Gilmara Holanda da CunhaAne Kelly Lima Ramalho
May 16, 2018·Journal of the American Chemical Society·Younong YuZhi-Cai Shi
Aug 28, 2021·International Journal of Molecular Sciences·Priya Antony, Ranjit Vijayan
Aug 8, 2021·British Journal of Pharmacology·Tito BornerBart C De Jonghe
May 20, 2020·Diabetes Spectrum : a Publication of the American Diabetes Association·John E Anderson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.